Intratumoral mycobiome heterogeneity influences the tumor microenvironment and immunotherapy outcomes in renal cell carcinoma
Science Advances · 11.04.2025 · 11 (15)
DOI: 10.1126/sciadv.adu1727 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 11.04.2025. Verfasst von Weiming Mou und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Tumor Microenvironment, Kidney Neoplasms, Immunotherapy. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The intratumoral mycobiome plays a crucial role in the tumor microenvironment, but its impact on renal cell carcinoma (RCC) remains unclear. We collected and quantitatively profiled the intratumoral mycobiome data from 1044 patients with RCC across four international cohorts, of which 466 patients received immunotherapy. Patients were stratified into mycobiota ecology-depauperate and mycobiota ecology-flourishing (MEF) groups based on fungal abundance. The MEF group had worse prognosis, higher fungal diversity, down-regulated lipid catabolism, and exhausted CD8 + T cells. We developed the intratumoral mycobiota signature and intratumoral mycobiota-related genes expression signature, which robustly predicted prognosis and immunotherapy outcomes in RCC and other cancers. Aspergillus tanneri was identified as a potential key fungal species influencing RCC prognosis. Our findings suggest that the intratumoral mycobiome suppresses lipid catabolism and induces T cell exhaustion in RCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China.
- Donghai County People's Hospital-Jiangnan University Smart Healthcare Joint Laboratory, Lianyungang 222000, China.
- Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.
- Department of Urology, Changhai Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.
- The First School of Clinical Medicine, Southern Medical University, Guangzhou, China.
- Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
ORCID-Profile: Weiming Mou, Zhixing Deng, Lingxuan Zhu, Aimin Jiang, Anqi Lin, Liling Xu, Zeji Guo, Lu Wang, Zaoqu Liu, Ting Wei, Jian Zhang, Liang Cheng, Haojie Huang, Rui Chen, Quan Cheng, Linhui Wang, Shuofeng Yuan, Peng Luo
Zitieren
APA
Mou, W., Deng, Z., Zhu, L., Jiang, A., Lin, A., Xu, L., Deng, G., Huang, H., Guo, Z., Zhu, B., Wu, S., Yang, T., Wang, L., Liu, Z., Wei, T., Zhang, J., Cheng, L., Huang, H., Chen, R., …, & Luo, P. (2025). Intratumoral mycobiome heterogeneity influences the tumor microenvironment and immunotherapy outcomes in renal cell carcinoma. Science Advances, 11(15). https://doi.org/10.1126/sciadv.adu1727
Vancouver
Mou W, Deng Z, Zhu L, Jiang A, Lin A, Xu L, et al. Intratumoral mycobiome heterogeneity influences the tumor microenvironment and immunotherapy outcomes in renal cell carcinoma. Science Advances. 2025;11(15). doi:10.1126/sciadv.adu1727
BibTeX
@article{Mou2025,
author = {Mou, Weiming and Deng, Zhixing and Zhu, Lingxuan and Jiang, Aimin and Lin, Anqi and Xu, Liling and Deng, Gengwen and Huang, Hongsen and Guo, Zeji and Zhu, Bang and Wu, Shuqi and Yang, Tao and Wang, Lu and Liu, Zaoqu and Wei, Ting and Zhang, Jian and Cheng, Liang and Huang, Haojie and Chen, Rui and Shao, Yi and Cheng, Quan and Wang, Linhui and Yuan, Shuofeng and Luo, Peng},
title = {Intratumoral mycobiome heterogeneity influences the tumor microenvironment and immunotherapy outcomes in renal cell carcinoma},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {15},
doi = {10.1126/sciadv.adu1727}
}
EUVIMED